Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

Saved in:
Bibliographic Details
Title: Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Authors: Delaloge, S.1 suzette.delaloge@gustaveroussy.fr, Pérol, D.2, Courtinard, C.3, Brain, E.4, Asselain, B.3, Bachelot, T.2, Debled, M.5, Dieras, V.4, Campone, M.6, Levy, C.7, Jacot, W.8, Lorgis, V.9, Veyret, C.10, Dalenc, F.11, Ferrero, J. M.12, Uwer, L.13, Kerbrat, P.14, Goncalves, A.15, Mouret-Reynier, M. A.16, Petit, T.17
Source: Annals of Oncology. Sep2016, Vol. 27 Issue 9, p1725-1732. 8p. 1 Diagram, 2 Charts, 2 Graphs.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdw260